BF-175

BF-175 is a selective SIRT1 agonist. BF175 increases SIRT1-mediated activation of PGC1-α, induces Apoptosis, induces Autophagy and inhibits SREBP activity. BF-175 protects against high glucose-mediated mitochondrial injury. BF-175 attenuates diabetic kidney disease progression. BF175 inhibits endometrial carcinoma[1][2].

Product Specifications

CAS Number

[1333375-02-2]

UNSPSC

12352005

Target

Apoptosis; Autophagy; Fatty Acid Synthase (FASN) ; PGC-1α; Sirtuin

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

Field of Research

Cancer; Metabolic Disease

Smiles

CC1(OB(C2=CC=C(C=C2)/C=C/C3=CC(Cl)=CC(Cl)=C3)OC1(C)C)C

Molecular Formula

C20H21BCl2O2

Molecular Weight

375.10

References & Citations

[1]Hong Q, et al. Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury. Kidney Int. 2018 Jun;93 (6) :1330-1343. |[2]Wang Q, et al. BF175 inhibits endometrial carcinoma through SREBP-regulated metabolic pathways in vitro. Mol Cell Endocrinol. 2021 Mar 1;523:111135.